Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $272,229 | $133,873 | $77,109 | $80,934 |
| - Cash | $11,525 | $13,771 | $7,431 | $15,120 |
| + Debt | $122,275 | $120,510 | $107,987 | $106,245 |
| Enterprise Value | $382,979 | $240,612 | $177,665 | $172,059 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$2 | -$10 | -$10 |
| % Margin | – | – | – | – |
| EBITDA | -$6,364 | -$5,693 | -$7,877 | -$10,232 |
| % Margin | – | – | – | – |
| Net Income | -$8,184 | -$7,521 | -$9,631 | -$11,967 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.19 |
| % Growth | -8.3% | 20% | 21.1% | – |
| Operating Cash Flow | -$3,542 | -$6,602 | -$7,689 | -$12,791 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,542 | -$6,602 | -$7,689 | -$12,791 |